TECENTRIQ SC DIN 02546310
Status: Marketed
Holder: HOFFMANN-LA ROCHE LIMITED
Available to quote
Health Canada record
| Active ingredient(s) | ATEZOLIZUMAB 125 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | L01FF05 ATEZOLIZUMAB |
|---|
| Original market date | 16-May-2024 |
|---|
| Current status date | 16-May-2024 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ATEZOLIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02462990 | TECENTRIQ | HOFFMANN-LA ROCHE LIMITED | Solution | ATEZOLIZUMAB 1200 MG | Marketed |
| 02492393 | TECENTRIQ | HOFFMANN-LA ROCHE LIMITED | Solution | ATEZOLIZUMAB 840 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 32880 | 2024-03-13 | Supplement to a New Drug Submission (SNDS) | New dosage regimen for the intravenous route of
administration; and
New subcutaneous route of administration with new
formulation and strength. |
Request a quote for TECENTRIQ SC
How to read a Canadian DIN record